Ayorinde I Soipe1, Lynn E Taylor2, Ajibola I Abioye3, Traci C Green4, Scott E Hadland5, Brandon D L Marshall6. 1. Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island. 2. Division of Infectious Diseases, The Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, Rhode Island. 3. Lifespan Center for International Health Research, Rhode Island Hospital/Warren Alpert Medical School, Providence, Rhode Island. 4. Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island; Department of Emergency Medicine, Boston University School of Medicine, Boston, Massachusetts; The Warren Alpert School of Medicine of Brown University, Rhode Island Hospital, Providence, Rhode Island. 5. Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts; Department of Pediatrics, Boston Medical Center, Boston, Massachusetts. 6. Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island. Electronic address: brandon_marshall@brown.edu.
Abstract
PURPOSE: Examine the prevalence of hepatitis C virus (HCV) screening, confirmatory testing, and care experiences among young adult nonmedical prescription opioid (NMPO) users. METHODS: We examined self-reported HCV screening history in a sample of 18- to 29-year-olds reporting past-month NMPO use, and we used modified Poisson regression to identify associated sociodemographic and drug use patterns. RESULTS: Among 196 participants, 154 (78.6%) reported prior HCV screening, among whom 18 (11.7%) reported positive results. Of these, 13 (72.2%) reported receiving a confirmatory test; 12 (66.7%) were referred for specialty HCV care. Screening was associated with injection drug use (adjusted prevalence ratio [APR] = 1.19; 95% confidence interval [CI] = 1.05-1.33) and history of hospitalization for psychiatric illness (APR = 1.23; 95% CI = 1.09-1.39). Younger participants (18-23 years) were less likely to have been screened (APR = .69; 95% CI = .57-.85). CONCLUSION: Among young adult NMPO users, post-HCV screening support and referral to care were inadequate.
PURPOSE: Examine the prevalence of hepatitis C virus (HCV) screening, confirmatory testing, and care experiences among young adult nonmedical prescription opioid (NMPO) users. METHODS: We examined self-reported HCV screening history in a sample of 18- to 29-year-olds reporting past-month NMPO use, and we used modified Poisson regression to identify associated sociodemographic and drug use patterns. RESULTS: Among 196 participants, 154 (78.6%) reported prior HCV screening, among whom 18 (11.7%) reported positive results. Of these, 13 (72.2%) reported receiving a confirmatory test; 12 (66.7%) were referred for specialty HCV care. Screening was associated with injection drug use (adjusted prevalence ratio [APR] = 1.19; 95% confidence interval [CI] = 1.05-1.33) and history of hospitalization for psychiatric illness (APR = 1.23; 95% CI = 1.09-1.39). Younger participants (18-23 years) were less likely to have been screened (APR = .69; 95% CI = .57-.85). CONCLUSION: Among young adult NMPO users, post-HCV screening support and referral to care were inadequate.
Authors: Stacey B Trooskin; Joanna Poceta; Caitlin M Towey; Annajane Yolken; Jennifer S Rose; Najia L Luqman; Ta-Wanda L Preston; Philip A Chan; Curt Beckwith; Sophie C Feller; Hwajin Lee; Amy S Nunn Journal: J Gen Intern Med Date: 2015-02-14 Impact factor: 5.128
Authors: Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas Journal: J Community Health Date: 2008-06
Authors: Ronald Valdiserri; Jag Khalsa; Corinna Dan; Scott Holmberg; Jon Zibbell; Deborah Holtzman; Robert Lubran; Wilson Compton Journal: Am J Public Health Date: 2014-03-13 Impact factor: 9.308
Authors: Natasha K Martin; Peter Vickerman; Jason Grebely; Margaret Hellard; Sharon J Hutchinson; Viviane D Lima; Graham R Foster; John F Dillon; David J Goldberg; Gregory J Dore; Matthew Hickman Journal: Hepatology Date: 2013-08-26 Impact factor: 17.425